The DNA damage repair gene PALB2 is well described as increasing risk of breast and ovarian cancer when mutated. In a sequencing study of hereditary diffuse gastric cancer (HDGC) families, Eleanor Fewings as a part of the Tischkowitz lab, has shown that predicted pathogenic mutations in PALB2 also occur in high risk HDGC families. Mutations in the E-cadherin gene CDH1 greatly impact HDGC risk, however many HDGC families are identified without mutations in this gene. For these families, the choice to undergo risk reducing surgery is based on poorly informed risk calculations. This study named new genetic candidates for HDGC risk including PALB2, ATR, NBN, and RECQL5. Identification of these genes could provide families with HDGC who don’t carry CDH1 pathogenic variants with improved information about the risks associated with their disease and allow them to make informed decisions about risk reduction and disease management.